Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ArQule names new chief medical officer
Dr Schwartz brings to ArQule significant experience in oncology drug development in both the biotechnology and pharmaceutical industries. He was most recently senior vice president of clinical and
Dr Schwartz brings to ArQule significant experience in oncology drug development in both the biotechnology and pharmaceutical industries. He was most recently senior vice president of clinical and
The company’s co-development partner, Johnson & Johnson Pharmaceutical R&D, also has filed a corresponding application with the European Medicines Evaluation Agency. The current approval was based on an
Boston Scientific said the transaction will raise pre-tax proceeds in excess of $100 million, the majority of which will be in cash, with a portion in a note
ArthroCare’s DoublePlay is manufactured from a proprietary composite material, the first composite to be used in sports medicine with clinically proven osteoconductivity and replacement by bone. This unique
The agreement, effective May 1, 2008, extends a long-standing relationship between Cigna and the hospital. Susan Pinnas, president and general manager of Cigna HealthCare of Florida, said: “We
The submitted label would extend the use of Erbitux for treatment of patients with recurrent or metastatic squamous cell cancer of the head and neck in combination with
The stem cell storage facility will initially provide stem cell banking for human umbilical cord blood stem cells, placenta stem cells, amniotic membrane stem cells, bone marrow stem
The new facilities offer 13,000 square feet of laboratory and office space that will support the company’s molecular diagnostic cancer testing services and research activities. Bernhard Sixt, president
The new office is expected to strengthen PPD’s presence in Eastern Europe beyond Russia and Ukraine, countries where the company is expanding through its pending acquisition of InnoPharm.
ThermoGenesis’s MarrowXpress (MXP) device is used to process bone marrow in a laboratory setting. The MXP is a derivative of the company’s approved AutoXpress platform that is used